Val­isure in the hot seat: New Form 483 over a 2021 in­spec­tion as CEO fires back

The no­to­ri­ous drug test­ing com­pa­ny Val­isure, which has made a name for it­self by forc­ing FDA’s hand with some of its safe­ty-re­lat­ed un­cov­er­ings, re­ceived a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER